Gain Therapeutics Valuation Multiples

Gain Therapeutics Overview

About Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Founded

2020

HQ

Employees

25

Website

gaintherapeutics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($21M)

EV

$58M

Valuation Multiples

Multiples.vc

Start free trial

Gain Therapeutics Financials

Gain Therapeutics reported last 12-month revenue of —.

In the same LTM period, Gain Therapeutics generated had net loss of ($21M).

Gain Therapeutics P&L

In the most recent fiscal year, Gain Therapeutics reported revenue of — and EBITDA of ($19M).

Gain Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Gain Therapeutics Stock Performance

Gain Therapeutics has current market cap of $78M, and enterprise value of $58M.

Gain Therapeutics' stock price is $1.84.

Gain Therapeutics Valuation Multiples

Gain Therapeutics trades at (3.1x) EV/EBITDA.

Gain Therapeutics Financial Valuation Multiples

As of April 11, 2026, Gain Therapeutics has market cap of $78M and EV of $58M.

Equity research analysts estimate Gain Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gain Therapeutics has a P/E ratio of (3.7x).

Gain Therapeutics Margins & Growth Rates

Gain Therapeutics' revenue in the last fiscal year declined by (100%).

Gain Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Gain Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Gain Therapeutics M&A Activity

Gain Therapeutics acquired XXX companies to date.

Last acquisition by Gain Therapeutics was on XXXXXXXX, XXXXX. Gain Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Gain Therapeutics Investment Activity

Gain Therapeutics invested in XXX companies to date.

Gain Therapeutics made its latest investment on XXXXXXXX, XXXXX. Gain Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).